Why BGPT?
logo

Traceable Claims in Immunology

Check what immune studies actually reported — results, scope, and sources you can verify.Know what the science actually supports before you trust the answer.

Press Enter ↵ to search claims



    Explore by Goal












     Quick Explanation


    The provided “best evidence” for **SCFA receptor pathways (FFAR3/GPR43→HDAC→NF-κB) in AxSpA human tissue** is **not actually present** in the research package you supplied: none of the included full-text excerpts are AxSpA human tissue studies, and the FFAR3(=GPR41/FFAR3 naming)→HDAC→NF-κB chain is **not directly evidenced** in AxSpA tissue here. What you *do* have is strong mechanistic evidence for **GPR43 (FFAR2)–SCFA signaling** engaging **innate immune transcriptional programs (e.g., IFN-β/ISGs and NF-κB–type dependence)** across **gut–lung/viral** and **airway inflammation** contexts, but that is **transferable mechanistic plausibility**, not disease-specific AxSpA tissue proof.


     Long Explanation


    Evidence check (BGPT battle-test): “SCFA receptor pathways (FFAR3 GPR43 HDAC NFkB) in AxSpA human tissue”
    Core problem: none of the supplied studies are AxSpA human tissue studies, and the specific signaling chain “FFAR3→GPR43→HDAC→NF-κB” is not demonstrated in AxSpA tissue in the material you provided.
    1) What’s actually in your dataset (receptor evidence, but not AxSpA tissue)
    Below are the mechanistic anchors you do have, mapped to receptors/signaling themes:
    Study (from provided package) Model / Tissue context (excerpt only) SCFA receptor(s) evidenced Immune pathway signal(s) in excerpt Matches AxSpA human tissue claim?
    10.1038/s41467-019-11152-6
    Acetate–GPR43→IFN-β–ISGs (gut–lung axis)     		Mouse lung (RSV); human infant genetics for IFNAR1 association (not AxSpA) GPR43 (FFAR2) explicitly; IFNAR dependence; acetate supplementation IFN-β, ISGs; mentions NF-κB dependency in mechanistic tooling No (different disease + no AxSpA tissue)
    10.1038/s41396-023-01541-7
    Rg3→Blautia→acetate/propionate→GPR43–cGAS-STING–IFN-I     		Mouse gut/immune axis; macrophages; viral infection models GPR43 (FFAR2) required; GPR41 not required IFN-I via cGAS–STING axis; IFNAR1 dependence No (not AxSpA tissue)
    10.1038/s41467-025-65573-7
    Eosinophil GPR43 shapes Siglec-Fhi neutrophils & Th17 airway inflammation     		Mouse airway inflammation (HDM/OVA asthma models) GPR43 in eosinophils; acetate can suppress phenotype in a GPR43-dependent way (sex note) Th17-linked outputs (Il1a/Il23a/Tnf/Tgfb1); IL-4 & GM-CSF synergy No (not AxSpA tissue; different immune ecology)
    10.1210/en.2013-1142
    GPR41/FFAR3 & GPR43/FFAR2 as SCFA cosensors (enterocytes vs neurons/leukocytes)     		Cell-type mechanistic mapping (enteroendocrine vs enteric neurons vs leukocytes) FFAR3 (GPR41) and FFAR2 (GPR43) Receptor co-sensing (excerpt provides no downstream HDAC/NF-κB chain results) No AxSpA tissue; excerpt lacks downstream chain evidence
    2) Visual: what receptors/signals are supported by the provided evidence (and what is missing)
    Interpretation discipline: “Supported” here means the included excerpts explicitly discuss that receptor and/or immune program in their mechanistic summary; it does not mean the specific AxSpA tissue and pathway chain (FFAR3→GPR43→HDAC→NF-κB) are evidenced.
    3) Causality strength: what kinds of evidence exist here?
    • Strong mechanistic causality for GPR43→IFN-β/ISGs exists in a gut–lung context with Gpr43-/- and Ifnar-/- dependence and acetate supplementation.
    • Strong mechanistic causality for GPR43→cGAS–STING→IFN-I exists in enteric viral models with IFN-I axis requirements and GPR43 requirement.
    • Sex-dependent modulation of GPR43-linked inflammatory phenotype is shown in airway inflammation models, but again not AxSpA.
    • Human relevance provided here is limited to non-AxSpA correlational genetics (IFNAR1 variant in RSV severity, not AxSpA tissue).
    • AxSpA human tissue and the specific FFAR3→GPR43→HDAC→NF-κB chain: not evidenced in your supplied excerpts. The “lung FFAR2/FFAR3 and IL-1β profiling” item has no results excerpt in the package.
    4) Limits & blind spots (what could mislead a “transfer” from these studies to AxSpA)
    • Disease mismatch: viral/airway/allergy models do not recapitulate AxSpA tissue immune circuits; mechanistic similarity (SCFA receptors) does not equal tissue-specific pathway activation.
    • Pathway-chain specificity: your claim specifies FFAR3 + GPR43 + HDAC + NF-κB in a single chain. Provided excerpts show GPR43-mediated IFN-I programs and mention NF-κB tooling, but do not establish the full HDAC–NF-κB link as a required intermediate.
    • Species translation: most causal work here is mouse-based; human evidence is correlational and not AxSpA.
    • Publication bias risk: your package includes high-scoring mechanistic studies, but that doesn’t guarantee negative/neutral AxSpA tissue results are absent—only that they weren’t included.
    • Missing data problem: the FFAR2/FFAR3 lung profiling entry has no results excerpt, so the pathway claim cannot be evaluated from the supplied material.
    5) What would be needed to truly support the original AxSpA tissue claim?
    A convincing package would include at least:
    • AxSpA human tissue (e.g., synovial/enthesis/IBD-adjacent mucosa/immune infiltrates) measuring receptor expression and SCFA exposure correlates.
    • HDAC involvement (e.g., HDAC activity changes or HDAC dependency experiments) and NF-κB nuclear translocation/target genes in AxSpA-relevant cells.
    • Receptor dependence: FFAR3- and/or GPR43-specific perturbations (KO/antagonist/agonist) showing required steps, not just “correlation.”
    Key correction
    Your “best evidence” statement currently overreaches the provided excerpts. The evidence you supplied most strongly supports GPR43-linked SCFA→innate antiviral/airway inflammatory programs (IFN-I via IFNAR/cGAS-STING; Th17/IL-23 axis context), but does not establish the specified AxSpA human tissue pathway chain.


    Feedback:    

    Updated: April 28, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    It will structure your provided studies into a receptor→pathway evidence matrix and generate a gap report for AxSpA human tissue missingness across FFAR3/GPR43/HDAC/NF-κB, using only the supplied excerpt fields.



     Hypothesis Graveyard


    A linear FFAR3→GPR43→HDAC→NF-κB cascade is the best explanation for AxSpA signaling based on the provided package—it is not supported by AxSpA tissue evidence here, so it should not be treated as established.


    “Any SCFA increase automatically reduces NF-κB in AxSpA tissue” is unlikely to be universally true; your provided evidence shows context-specific immune programs (IFN-I, Th17 modulation), implying nonuniform downstream routing.

     Science Art


    Best Evidence: SCFA receptor pathways (FFAR3 GPR43 HDAC NFkB) in AxSpA human tissue Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending